NCT05626114 - A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 23, 2023

Primary Completion Date

March 1, 2031

Study Completion Date

March 1, 2031

Conditions

Geographic Atrophy

Interventions

BIOLOGICAL

OpRegen

OpRegen dose up to approximately 200,000 cells will be delivered into the subretinal space

Trial Locations (15)

33711

RECRUITING

Retina Vitreous Associates of Florida, St. Petersburg

77401

RECRUITING

Retina Consultants of Texas, Bellaire

90211

RECRUITING

Retina-Vitreous Associates Medical Group, Beverly Hills

95825

RECRUITING

Retinal Consultants Medical Group, Sacramento

99204

RECRUITING

Spokane Eye Clinical Research;Spokane Eye Surgery Center, Spokane

6423906

RECRUITING

Tel Aviv Sourasky MC, Tel Aviv

9112001

RECRUITING

Hadassah MC, Jerusalem

94109-5520

RECRUITING

West Coast Retina, San Francisco

21209-2219

RECRUITING

The Retina Care Center, Baltimore

63128-1729

RECRUITING

The Retina Institute, St Louis

45242-5537

RECRUITING

Cincinnati Eye Institute, Blue Ash

19107-5109

RECRUITING

Mid Atlantic Retina, Philadelphia

37203-1513

RECRUITING

Tennessee Retina PC, Nashville

78750-2298

RECRUITING

Austin Clinical Research, LLC, Austin

24502-4271

RECRUITING

Piedmont Eye Center, Lynchburg